Impact of gene patents and licensing practices on access to genetic testing for inherited susceptibility to cancer: comparing breast and ovarian cancers with colon cancers.
Genetic testing for inherited susceptibility to breast and ovarian cancer can be compared with similar testing for colorectal cancer as a "natural experiment." Inherited susceptibility accounts for a similar fraction of both cancers and genetic testing results guide decisions about options for prophylactic surgery in both sets of conditions. One major difference is that in the United States, Myriad Genetics is the sole provider of genetic testing, because it has sole control of relevant patents for BRCA1 and BRCA2 genes, whereas genetic testing for familial colorectal cancer is available from multiple laboratories. Colorectal cancer-associated genes are also patented, but they have been nonexclusively licensed. Prices for BRCA1 and 2 testing do not reflect an obvious price premium attributable to exclusive patent rights compared with colorectal cancer testing, and indeed, Myriad's per unit costs are somewhat lower for BRCA1/2 testing than testing for colorectal cancer susceptibility. Myriad has not enforced patents against basic research and negotiated a Memorandum of Understanding with the National Cancer Institute in 1999 for institutional BRCA testing in clinical research. The main impact of patenting and licensing in BRCA compared with colorectal cancer is the business model of genetic testing, with a sole provider for BRCA and multiple laboratories for colorectal cancer genetic testing. Myriad's sole-provider model has not worked in jurisdictions outside the United States, largely because of differences in breadth of patent protection, responses of government health services, and difficulty in patent enforcement.
Cook-Deegan
Robert
R
Center for Public Genomics, Center for Genome Ethics, Law and Policy, Institute for Genome Sciences and Policy, Duke University, Durham, NC 27708, USA. gelp@duke.edu
DeRienzo
Christopher
C
Carbone
Julia
J
Chandrasekharan
Subhashini
S
Heaney
Christopher
C
Conover
Christopher
C
D019313:BRCA1 Protein / Q000235:genetics; D024682:BRCA2 Protein / Q000235:genetics; D001943:Breast Neoplasms / Q000175:diagnosis / Q000235:genetics*; D003110:Colonic Neoplasms / Q000175:diagnosis / Q000235:genetics*; D003362:Cost-Benefit Analysis; D005260:Female; D005796:Genes; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D005820:Genetic Testing / Q000191:economics / Q000941:ethics*; D006297:Health Services Accessibility / Q000191:economics / Q000941:ethics; D006801:Humans; D008007:Licensure, Medical / Q000941:ethics*; D008297:Male; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000235:genetics*; D010330:Patents as Topic / Q000941:ethics*
D019313:BRCA1 Protein; D024682:BRCA2 Protein
Ann Intern Med. 2006 Mar 21;144(6):397-406
16549852
Ann Intern Med. 1998 Nov 15;129(10):787-96
9841584
Am J Manag Care. 2005 Oct;11(10):601-8
16232001
Genet Med. 2010 Apr;12(4 Suppl):S39-70
20393310
JAMA. 2007 Dec 26;298(24):2869-76
18159056
Hum Mutat. 2000;15(1):57-61
10612823
J Natl Compr Canc Netw. 2010 Jan;8(1):8-61
20064289
Ann Intern Med. 2005 Sep 6;143(5):355-61
16144894
CA Cancer J Clin. 2008 May-Jun;58(3):130-60
18322143
Clin Chem. 1999 Mar;45(3):324-30
10053032
BMC Genet. 2007 Oct 04;8:68
17916242
Int J Technol Assess Health Care. 2003 Spring;19(2):287-300
12862187
JAMA. 2006 Mar 22;295(12):1379-88
16551709
Genet Med. 2005 Mar;7(3):191-7
15775755
Genet Test. 2007 Spring;11(1):101-10
17394399
N Y Times Web. 2006 Sep 3;:A1, A20
17265567
Genet Med. 2009 Jan;11(1):42-65
19125127
Gastroenterology. 2001 Jul;121(1):198-213
11438509
Genet Med. 2009 Jan;11(1):35-41
19125126
Genet Med. 2001 Nov-Dec;3(6):422-5
11715007
Soc Stud Sci. 2005 Feb;35(1):5-40
15991444
CA Cancer J Clin. 2007 Mar-Apr;57(2):75-89
17392385
J Clin Oncol. 1998 Mar;16(3):979-85
9508180
Int J Technol Assess Health Care. 2000 Winter;16(1):178-89
10815363
J Med Genet. 1999 Oct;36(10):747-53
10528853
MMWR Morb Mortal Wkly Rep. 2004 Jul 16;53(27):603-6
15254451
Am J Manag Care. 2004 Jul;10(7 Pt 1):425-32
15298364
Evid Rep Technol Assess (Full Rep). 2007 May;(150):1-180
17764220
J Mol Diagn. 2003 Feb;5(1):3-8
12552073
Clin Genet. 2000 May;57(5):370-5
10852371
Cancer J Sci Am. 2000 Jan-Feb;6(1):13-20
10696733
Cancer. 2002 Mar 15;94(6):1876-85
11920551
Dis Colon Rectum. 2003 Aug;46(8):1001-12
12907889
Aust N Z J Public Health. 2003;27(1):34-40
14705265
Pediatrics. 2006 May;117(5 Pt 2):S287-95
16735255
Eur J Hum Genet. 2002 Oct;10(10):599-606
12357330
MMWR Morb Mortal Wkly Rep. 2003 Mar 14;52(10):193-6
12653456
Gastroenterology. 1996 Apr;110(4):1020-7
8612988
J Genet Couns. 2001 Aug;10(4):331-41
26141158
Hum Mutat. 2004 Dec;24(6):534
15532023
Cancer Epidemiol Biomarkers Prev. 2002 Jan;11(1):79-87
11815404
J Clin Oncol. 2002 Jan 1;20(1):9-16
11773148
Am J Manag Care. 2003 Jul;9(7):493-500
12866628
Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):1003-7
15824179
Ann Surg Oncol. 2000 Jun;7(5):325-32
10864338
Nat Clin Pract Gastroenterol Hepatol. 2006 Dec;3(12):670-9
17130877